Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia
Key facts
- Where
- Nanjing, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07075237, who can take part
Where in China
- Nanjing Brain HospitalNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jiangsu Province Nanjing Brain Hospital
- Trial code
- NCT07075237
- Record updated
- 29 September 2025
- Original description
To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social functionRead full original descriptionShow less
A Study on the Efficacy and Functional Recovery of Switching From Oral Antipsychotics to Paliperidone Palmitate Injection in the Treatment of Schizophrenia
To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function
Inclusion: Outpatients or inpatients meeting DSM-5 diagnostic criteria forschizophrenia; Aged 18-65 years (inclusive), regardless of gender; Currently receiving first- or second-generation oral antipsychotics (excluding clozapine) with stable condition as assessed by the investigator, and PANSS total score ≤80 at screening and baseline; Signed informed consent by the patient and/or guardian.
Exclusion: Comorbid psychiatric diagnoses other than schizophrenia; Severe physical diseases, intellectual disability, organic brain disorders, or mental disorders due to physical illnesses; History of psychoactive substance abuse (excluding tobacco) within the past 12 months, or significant suicidal/violent tendencies; Current or history of tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), or severe extrapyramidal symptoms (EPS); Treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic regimens of different compounds); Hypersensitivity or inefficacy to risperidone or paliperidone; 8. Pregnancy, lactation, planned pregnancy, or failure to use effective contraception during the study; Other conditions deemed unsuitable by the investigator. |; QTc interval >450 ms (male) or >460 ms (female).